Lung cancer

EGRX FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Eagle Pharmaceuticals (EGRX) Investors with Substantial Losses to Contact Firm Before Feb. 9th Deadline in Securities Fraud Class Action

Retrieved on: 
Thursday, February 8, 2024

SAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) investors who suffered substantial losses to submit your losses now .
  • The line of credit reduction follows the filing of a securities fraud class action suit against Eagle and its executives challenging the company’s admitted improper accounting.
  • The truth began to emerge on Nov. 9, 2023, when the Company announced that it would not be timely filing its financial report for 3Q 2023.
  • Then, on Nov. 29, 2023, Eagle announced that its board of directors accepted the resignation of its CEO (Scott Tarriff) effective immediately.

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

Retrieved on: 
Thursday, February 8, 2024

For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR).

Key Points: 
  • For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR).
  • The designation enables healthcare practices and providers utilizing iKnowMed℠ electronic health record (EHR) to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.
  • As a CMS-approved QCDR, Practice Insights ℠, a performance analytics tool powered by Ontada ®, can collect and report clinical data on behalf of clinicians for standard MIPS measures.
  • It also continues to provide meaningful insights to improve care while simultaneously easing the burden of participating in CMS regulatory programs.

Center for Asbestos Related Disease Continues FREE Asbestos & Lung Cancer Screenings

Retrieved on: 
Thursday, February 8, 2024

LIBBY, Mont., Feb. 8, 2024 /PRNewswire/ -- The Center for Asbestos Related Disease (CARD) in Libby, Montana continues with the organization's outreach efforts to extend free community asbestos health and lung cancer screening programs.

Key Points: 
  • LIBBY, Mont., Feb. 8, 2024 /PRNewswire/ -- The Center for Asbestos Related Disease (CARD) in Libby, Montana continues with the organization's outreach efforts to extend free community asbestos health and lung cancer screening programs.
  • Each year, the CARD Clinic provides free screenings to more than 500 people for asbestos related lung diseases and over 500 more for lung cancer screening.
  • These important programs are funded through a federal grant awarded to CARD by the Center for Disease Control (CDC).
  • Participation in CARD's asbestos health screening and lung cancer screening programs is free for those who qualify.

HEALWELL AI’s Pentavere Referenced by Several Leading Global Organizations for its Strength in Artificial Intelligence for Preventative Care

Retrieved on: 
Thursday, February 8, 2024

Pentavere continues to publish ground-breaking AI work accepted at prestigious global medical conferences and leading oncology organizations.

Key Points: 
  • Pentavere continues to publish ground-breaking AI work accepted at prestigious global medical conferences and leading oncology organizations.
  • In the past quarter Pentavere presented its AI work, in partnership with leading academic centers and global pharmaceutical companies at a number of prestigious conferences.
  • TORONTO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is pleased to announce that its subsidiary Pentavere Research Group Inc. (“Pentavere”), continues to publish ground-breaking AI work accepted at prestigious global medical conferences and leading oncology organizations.
  • Using Artificial Intelligence to automate the extraction of staging criteria from the electronic health records of oropharyngeal cancer patient.

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

Retrieved on: 
Thursday, February 8, 2024

Selective BRM inhibition has been a sought-after objective in cancer research for many years.

Key Points: 
  • Selective BRM inhibition has been a sought-after objective in cancer research for many years.
  • A variety of tumor types, including NSCLC, are known to have mutations in BRG1, which we believe make them dependent on BRM activity for their survival.
  • Selective blocking of BRM activity is considered a promising strategy for causing tumor cell death while sparing healthy cells.
  • The collaboration includes a US 50/50 co-development and co-commercialization agreement for Foghorn’s Selective BRM oncology program and an additional undisclosed oncology target.

Global Life Sciences Data Leader H1 Releases GenosAI™ Pro to Empower Clinical Ops Leaders with Conversational AI

Retrieved on: 
Wednesday, February 7, 2024

NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- H1 , the leading source of truth for global healthcare professionals, clinical trial, and research information for life sciences, announces the launch of GenosAI™ Pro, a new addition to its conversational AI toolkit.

Key Points: 
  • NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- H1 , the leading source of truth for global healthcare professionals, clinical trial, and research information for life sciences, announces the launch of GenosAI™ Pro, a new addition to its conversational AI toolkit.
  • GenosAI is the conversational AI backbone powering all H1 solutions.
  • Building on the success of GenosAI Lite released in 2023, the new GenosAI Pro brings even more advanced AI-powered features and capabilities to Trial Landscape.
  • “GenosAI Pro marks a significant leap forward in applying the power of generative AI to clinical research, offering unmatched insights and efficiencies.

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Retrieved on: 
Wednesday, February 7, 2024

AUSTIN, Texas, Feb. 7, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the expansion of its nonclinical programs into new indications through Sponsored Research Agreements and Material Transfer Agreements with multiple academic research collaborators to study TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The new indications being evaluated include ALK-positive lung cancer and other additional programs that are not disclosed at this time.

Key Points: 
  • The new indications being evaluated include ALK-positive lung cancer and other additional programs that are not disclosed at this time.
  • "Research indicates that the TUSC2 gene used in REQORSA may benefit many types of cancers and potentially the treatment of other diseases.
  • Research collaborators at the Rogel Cancer Center's Judith Tam ALK Lung Cancer Research Initiative are studying the combination of Genprex's REQORSA, which uses the TUSC2 tumor suppressor gene, with various ALK inhibitors.
  • Genprex believes this system allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer.

MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Retrieved on: 
Wednesday, February 7, 2024

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications .

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications .
  • “This publication highlights a rather unique dual mechanism of action for THIO as a first-in-clinic telomere-targeted anticancer agent for potential treatment of SCLC,” said Sergei M. Gryaznov, PhD., MAIA’s Chief Scientific Officer.
  • Key findings in the published paper include:
    “With few, if any, effective treatments for small cell lung cancer, there is a widespread need for innovative therapeutic strategies.
  • The positive outcomes reported in our publication show THIO’s potential as a new therapeutic approach,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer.

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, February 7, 2024

Bristol Myers Squibb (NYSE: BMY) today announced two regulatory acceptances for applications for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced two regulatory acceptances for applications for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC).
  • "Between 30% to 55% of non-small cell lung cancer patients who undergo surgery will experience disease recurrence.
  • The study also showed benefits in key secondary endpoints including pathologic complete response (pCR) and major pathologic response (MPR).
  • Opdivo and Opdivo-based combinations have shown efficacy benefits in the neoadjuvant, adjuvant or perioperative settings across four cancers to date, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.

King Charles is having cancer treatment. What can he, and others with cancer, expect?

Retrieved on: 
Wednesday, February 7, 2024

The type of cancer has not been revealed, but it has been confirmed it is not prostate cancer.

Key Points: 
  • The type of cancer has not been revealed, but it has been confirmed it is not prostate cancer.
  • So what can King Charles and the millions of others who are newly diagnosed with cancer each year expect?

What actually is cancer?

  • Normally, cells multiply and die in a regulated way, so each new cell replaces a cell that is lost.
  • The cancer cells can break away and travel through the bloodstream or lymph vessels to other parts of the body.
  • If the primary cancer cells grow and form another tumour at a new site, it is called a secondary cancer or metastasis.


Read more:
How does cancer spread to other parts of the body?

Millions of new cases each year

  • And King Charles’ diagnosis is one of roughly 19.3 million new cases of cancer diagnosed worldwide each year.
  • The most common cancers can vary between countries, due to a number of factors such as genetics, lifestyle and environment.
  • In Australia, for example, the most common cancers are prostate, breast, skin melanoma, colorectal cancer and lung cancer.

Cancer accounts for 1 in 6 deaths

  • Worldwide, leading cancer-related deaths are from lung, colorectal, stomach, breast, pancreatic, oesophageal, prostate and liver cancer.
  • In 2023, there were roughly 165,000 cases of cancer diagnosed and 51,000 cancer deaths in Australia.

But more people are surviving cancer

  • Advances in medicine and treatments for cancer have led to more people surviving cancer.
  • This therapy destroys cancer cells using a controlled dose of radiation to kill or damage cancer cells so they cannot grow, multiply or spread, while sparing surrounding healthy tissue.
  • There is also “CAR T-cell therapy”, which harnesses the body’s own immune system to fight against cancer.
  • Thanks to COVID, mRNA technology and other nanoparticle delivery systems are also an area yielding promising results for cancer vaccines.

Do treatments work?

  • With such new treatments, cancer survival rates have improved significantly.
  • In Australia, for example, five-year survival rates improved from 52% to 70% from 1989–1993 to 2014–2018.

In a nutshell


King Charles’ cancer diagnosis, at the age of 75, is one of millions of new cancer diagnoses globally. While cancer remains a leading cause of death worldwide, survival rates are improving thanks to extensive advances in treatments and treatment options.

Read more:
What happens if King Charles can no longer perform his duties?


Sathana Dushyanthen does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.